Claims
- 1. A method of inhibiting propagation of an infectious agent associated with an infectious disease, comprising;
contacting the infectious agent with an oligonucleotide that comprises one or more LNA units; wherein contacting of the LNA oligonucleotide to the infectious agent modulates expression of a gene of the infectious agent.
- 2. The method of claim 1 wherein the LNA oligonucleotide inhibits expression of a gene of the infectious agent.
- 3. The method of claim 1 or 2 wherein contacting of the LNA oligonucleotide inhibits the functionality of a gene involved in the pathogenesis of the infectious agent
- 4. The method of any one of claims 1 through 3 wherein the LNA oligonucleotide is complementary to a gene of the infectious agent.
- 5. A method of modulating expression of a gene from an infectious agent associated with an infectious disease, comprising;
contacting an oligonucleotide sequence of an infectious agent with a complementary oligonucleotide sequence that comprises one or more LNA units; whereby contacting of the LNA oligonucleotide sequence to the infectious agent modulates expression of a gene coding for the infectious agent.
- 6. The method of any one of claims 1 through 5 wherein the contacting inhibits infectious agent protein or peptide production associated with propagation of the infectious agent.
- 7. The method of any one of claims 1 through 6 wherein the LNA oligonucleotide is administered to cells or tissue that comprises the infectious agent.
- 8. The method of any one of claims 1 through 7 wherein the infectious agent gene or oligonucleotide comprises single stranded DNA, double stranded DNA, cDNA or RNA.
- 9. The method of any one of claims 1 through 8 wherein the infectious agent is a virus.
- 10. The method of any one of claims 1 to 9 wherein contacting with the LNA oligonucleotide inhibits viral protein synthesis, viral cell membrane synthesis, viral nucleic acid synthesis, viral replication, or viral genes encoding host immune modulating functions.
- 11. The method of any one of claims 1 to 10 wherein the infectious agent gene comprises at least a portion of a sequence identified in table 3 above.
- 12. The method of any one of claims 1 through 8 wherein the infectious agent is a bacterium.
- 13. The method of claim 12 wherein the bacterium is identified in table 4 above.
- 14. The method of claim 12 or 13 wherein the bacterium comprises a gene or oligonucleotide having a sequence that at least a portion of which is identified in table 5 or 6 above.
- 15. The method of any one of claims 1 through 8 wherein the infectious agent is or associated with a protozoa or fungi.
- 16. The method of any one of claims 1 through 15 wherein the LNA oligonucleotide hybridizes with messenger RNA of a gene or oligonucleotide of the infectious agent to inhibit expression thereof.
- 17. The method of any one of claims 1 through 16 wherein the LNA oligonucleotide is administered to mammalian cells.
- 18. A method of treating a mammal suffering from or susceptible to an infectious disease or disorder, comprising:
administering to the mammal a therapeutically effective amount of an oligonucleotide that comprises one or more LNA units.
- 19. The method of claim 19 wherein the infectious disease is caused by or associated with a virus, bacteria, protozoa or fungi.
- 20. The method of claim 19 or 20 wherein the infectious agent is present in a lung, heart, liver, stomach, intestine, bowel, prostate, brain, spinal cord, sinuses, urinary tract or ovaries of the mammal.
- 21. The method of any one of claims 18 through 20 wherein the disease or disorder is associated with undesired expression of at least a portion of a sequence identified in table 2, 4 or 5 above.
- 22. The method of any one of claims 18 through 21 wherein the administered LNA oligonucleotide hybridizes with messenger RNA of the gene to inhibit expression thereof.
- 23. The method of any one of claims 18 through 22 wherein administering the LNA oligonucleotide results in inhibition of gene expression.
- 24. The method of any one of claims 1 through 23 wherein the LNA oligonucleotide contains a total of from about 8 to about 100 base units.
- 25. The method of any one of claims 1 through 23 wherein the LNA oligonucleotide contains a total of from about 8 to about 60 base units.
- 26. The method of any one of claims 1 through 23 wherein the LNA oligonucleotide contains a total of from about 10 to about 40 base units.
- 27. The method of any one of claims 1 through 23 wherein the LNA oligonucleotide contains a total of from about 10 to about 20 base units.
- 28. The method of any one of claims 1 through 27 wherein the LNA oligonucleotide contains a total of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 LNA units.
- 29. The method of any one of claims 1 through 28 wherein the LNA oligonucleotide comprises one or more units of Formula I as that Formula I is defined above.
- 30. The method of any one of claims 1 through 29 wherein the LNA oligonucleotides comprises one or more units of scheme II as that scheme II is defined above.
- 31. A method for treating cells comprising an infectious agent, comprising:
administering to the cells an oligonucleotide sequence that comprises one or more LNA units, the cells comprising an oligonucleotide sequence of an infectious agent.
- 32. The method of claim 31 wherein the LNA oligonucleotide sequence is complementary to the infectious agent oligonucleotide sequence.
- 33. The method of claim 31 or 32 wherein the cells are mammalian cells.
- 34. The method of any one of claims 31 through 33 wherein the cells are infected with a bacteria, protozoa or fungi.
- 35. The method of any one of claims 31 through 34 wherein the LNA oligonucleotide contains a total of from about 8 to about 100 base units.
- 36. The method of any one of claims 31 through 34 wherein the LNA oligonucleotide contains a total of from about 8 to about 60 base units.
- 37. The method of any one of claims 31 through 34 wherein the LNA oligonucleotide contains a total of from about 10 to about 40 base units.
- 38. The method of any one of claims 31 through 34 wherein the LNA oligonucleotide contains a total of from about 10 to about 20 base units.
- 39. The method of any one of claims 31 through 38 wherein the LNA oligonucleotide contains a total of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 LNA units.
- 40. The method of any one of claims 31 through 39 wherein the LNA oligonucleotide comprises one or more units of Formula I as that Formula I is defined above.
- 41. The method of any one of claims 31 through 40 wherein the LNA oligonucleotides comprises one or more units of scheme II as that scheme II is defined above.
- 42. Use of an LNA oligonucleotide for the preparation of a medicament for the preparation of an agent for the treatment of a bacterial, protozoa or fungi infection.
- 43. The use of claim 42 wherein the LNA oligonucleotide contains a total of from about 8 to about 100 base units.
- 44. The use of claim 42 wherein the LNA oligonucleotide contains a total of from about 8 to about 60 base units.
- 45. The use of claim 42 wherein the LNA oligonucleotide contains a total of from about 8 to about 40 base units.
- 46. The use of claim 42 wherein the LNA oligonucleotide comprises from about 10 to about 20 base units.
- 47. The use of any one of claims 42 through 46 wherein the LNA oligonucleotide contains a total of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 LNA units.
- 48. The use of any one of claims 42 through 47 wherein the LNA oligonucleotide comprises one or more units of Formula I as that Formula I is defined above.
- 49. The use of any one of claims 42 through 48 wherein the LNA oligonucleotide comprises one or more units of scheme II as that scheme is defined above.
- 50. A pharmaceutical composition comprising an LNA oligonucleotide packaged together with written instructions for use of the oligonucleotide for the treatment of a disease or disorder associated with a bacterial, protozoa or fungi infection.
- 51. The pharmaceutical composition of claim 50 wherein the LNA oligonucleotide contains a total of from about 8 to about 100 base units.
- 52. The pharmaceutical composition of claim 50 wherein the LNA oligonucleotide contains a total of from about 8 to about 60 base units.
- 53. The pharmaceutical composition of claim 50 wherein the LNA oligonucleotide contains a total of from about 10 to about 40 base units.
- 54. The pharmaceutical composition of claim 50 wherein the LNA oligonucleotide comprises from about 10 to about 20 base units.
- 55. The pharmaceutical composition of any one of claims 50 through 54 wherein the LNA oligonucleotide contains a total of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 LNA units.
- 56. The pharmaceutical composition of any one of claims 50 through 55 wherein the LNA oligonucleotide comprises one or more units of Formula I as that Formula I is defined above.
- 57. The pharmaceutical composition of any one of claims 50 through 56 wherein the LNA oligonucleotide comprises one or more units of scheme II as that scheme is defined above.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional application No. 60/291,830 filed May 18, 2001, the entirety of which is incorporated by reference herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60291830 |
May 2001 |
US |